Dear Madison,
Your actions have revealed a troubling level of greed.
The exorbitant price of Mylan’s EpiPen, now at $600, and the newly announced $300 generic auto-injector, effectively places a critical medication beyond the financial reach of countless American families. The production cost of the EpiPen is only a few dollars, yet you have raised its price by $500 over the past decade. Your recent statement about introducing a generic version at “half” the price is misleading. Families dealing with allergies are not fooled; you intend to sell us a generic EpiPen—previously available for $100 in 2007—at a staggering markup of 300%.
Did you believe we would express gratitude for this? Or did you think we would be so bewildered that we wouldn’t notice the truth?
The fact that you are reducing the price while it remains three times higher than just a few years ago highlights the relentless nature of your profit-driven agenda. Families with allergies can’t simply budget for these life-saving medications as one would for a car. We require them consistently, and since they expire annually, the financial burden of acquiring new EpiPens is a constant struggle. Many households need more than one pack; for instance, my family requires three even before our daughter starts school. I know families who need five or six packs.
Those who can afford your inflated prices do so out of necessity; the alternative is potentially life-threatening for our loved ones. There are no viable alternatives on the market, which allows you to raise prices repeatedly without consequence.
You argue that lowering the EpiPen price would harm Mylan, yet your compensation has increased by over 670% since you took charge of this product nine years ago. With an annual income of $19 million, it appears that no amount of wealth can quell your desire for more.
While you accumulate substantial profits, we are left to purchase just enough medication to navigate another year of uncertainty, or perhaps merely to survive the next anaphylactic reaction. Your refusal to lower EpiPen prices makes it clear that you prioritize Mylan’s profits and your own enrichment over the lives of my daughter and the millions of families who rely on these essential medications.
Consider this, Madison:
Every lavish meal you enjoy is funded by families who skip meals to ensure their children have access to EpiPens. Each luxury vehicle or vacation home you acquire is financed by parents who have had to forgo mortgage payments just to afford these life-saving products for their children with allergies. There are countless families who are unable to support your exorbitant salary, as they either go without EpiPens or rely on outdated ones because they cannot afford the necessary replacements.
You can present yourself as an advocate for allergy sufferers, but your actions tell a different story. You can distribute coupons or propose new, unaffordable products, but these gestures do not address the core issue: your price-gouging tactics have severely impacted allergy families for years.
Philanthropic gestures do not equate to genuine compassion. They merely serve to mask the reality of your exploitation of hardworking families. Your financial contributions to allergy organizations do not signify understanding; they represent a fraction of the profits you have taken from those in need.
If you were to experience a life-threatening allergy, I assure you that our community would not hesitate to use our EpiPens to save your life, despite the high cost that you have imposed on us. That is the true character of the allergy community—one that you have chosen to exploit for your gain.
I am grateful that my daughters will grow up in a community that values compassion and kindness. They will learn to be empathetic and prioritize the well-being of others, unlike the model you have set.
In conclusion, your actions serve as a cautionary tale for my daughters about the importance of integrity and compassion over personal gain. They will strive to be the opposite of who you are—caring and selfless individuals who prioritize saving lives over making profits.
For those seeking further insights into fertility and home insemination, resources such as this article on fertility supplements and this guide on the couples’ fertility journey can provide valuable information. Additionally, the American College of Obstetricians and Gynecologists offers excellent guidance on addressing infertility and related topics.
Keyphrase: EpiPen pricing and compassion
Tags: “home insemination kit”, “home insemination syringe”, “self insemination”